Cystic Fibrosis

Key Points

• Cystic fibrosis is an autosomal recessive disease caused by CFTR dysfunction.
• Thick, sticky secretions obstruct airways and increase recurrent respiratory infection risk.
• Pancreatic duct obstruction reduces digestive-enzyme delivery and can cause malabsorption.
• Diagnosis commonly uses newborn heel-stick screening plus sweat chloride confirmation and genetic testing.
• Long-term care combines airway clearance, nutrition support, mutation-targeted therapy, and infection prevention.
• Progressive multisystem disease burden can shorten life span and requires long-horizon care planning.
• Recurrent hospitalization burden is common in advanced disease and should be incorporated into longitudinal care planning.

Pathophysiology

CF results from inherited mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Defective chloride transport leads to dehydrated secretions that become thick and difficult to clear.

In the lungs, retained secretions narrow airways and support chronic infection-inflammation cycles that can progressively damage lung tissue. Frequent colonization patterns include Pseudomonas, Haemophilus influenzae, and Staphylococcus aureus in vulnerable patients. In the pancreas, thick secretions block enzyme flow into the intestine, reducing nutrient absorption and growth.

CF burden is substantial despite improved outcomes: in the United States, more than 30,000 people are affected, and recurrent admissions remain common in severe disease. Median survival has improved into adulthood, but pulmonary decline remains the major driver of morbidity and mortality.

Classification

• Pulmonary-dominant pattern: Recurrent cough, mucus retention, infection exacerbations, and chronic lung decline.
• Pancreatic/nutritional pattern: Malabsorption with weight-gain and nutrition challenges.
• Mutation-targeted therapy eligible pattern: Selected CFTR variants that respond to CFTR modulators.
• Inheritance-risk pattern: If both parents carry CFTR mutation, each pregnancy has a one-in-four affected risk and one-in-two carrier risk.

Nursing Assessment

NCLEX Focus

Prioritize airway clearance, oxygenation trend, and nutrition status in every CF assessment cycle.

• Assess cough pattern, sputum burden, dyspnea, and breath-sound changes.
• Monitor fever and exacerbation cues suggesting acute respiratory infection.
• Track weight trend, appetite, stool pattern, and signs of malabsorption.
• Review newborn-screening history, sweat chloride results, and genetic-testing status.
• Assess family history and known carrier status for inherited-risk counseling.
• Assess infant and pediatric cues such as meconium ileus history, salty sweat report, and early failure-to-thrive pattern.
• Assess multisystem symptom burden: abdominal bloating, fatty stools, constipation, bowel-obstruction history, and GU fertility concerns.
• Assess medication adherence and technique for inhaled and mucus-thinning therapies.
• Monitor functional status and fatigue progression to identify worsening pulmonary reserve.
• Assess recent admission frequency and home-treatment burden to prioritize discharge planning and continuity support.
• Assess caregiver and patient stress burden, coping capacity, and support-resource needs in chronic disease management.
• In preconception or pregnancy care, assess for increased respiratory infection burden, impaired airway clearance, pancreatic insufficiency, and nutrition decline.
• In reproductive planning, coordinate partner carrier testing discussion to estimate fetal inheritance risk.

Diagnostic Testing

• Universal newborn screening: Heel-stick blood screening at birth in U.S. practice pathways.
• Sweat chloride test: Confirmatory testing after positive screening; elevated sodium/chloride in collected sweat supports diagnosis.
• Genetic testing: Defines CFTR mutation profile and supports carrier/family counseling.
• Sputum culture and Gram stain: Supports targeted treatment when pulmonary infection is suspected.
• Liver-function trends: May show elevated values with hepatobiliary involvement.
• 72-hour stool testing: Can show increased fecal fat with low albumin context in malabsorption patterns.
• Chest imaging (usually x-ray): Tracks exacerbation burden and structural progression.
• Pulmonary function testing: Quantifies severity and disease progression over time.
• ABG trend: May show hypoxemia and low pH in advanced respiratory decline.

Nursing Interventions

• Support airway-clearance routines and secretion-management therapies as ordered.
• Administer and monitor prescribed bronchodilators, mucolytics, anti-inflammatory agents, and antibiotics.
• Prepare for and support route-specific medication delivery (oral, IV, or inhaled) and ordered imaging follow-up.
• Provide supplemental oxygen support when ordered for hypoxemia.
• Coordinate nutrition-focused care planning for absorption challenges and growth support.
• Support GI management, including intake assessment, pancreatic-enzyme administration, salt supplementation, and bowel-function monitoring.
• Coordinate airway-clearance plans with respiratory therapy and physical therapy when ordered.
• Reinforce infection-prevention practices, including hand hygiene and symptom-reporting thresholds.
• Teach family and patient how mutation-targeted medications (CFTR modulators) fit the overall plan when prescribed.
• In pregnancy-risk pathways, coordinate multidisciplinary respiratory and nutrition follow-up with closer monitoring intervals.
• Escalate for worsening respiratory distress, refractory hypoxemia, or frequent exacerbations.
• Reevaluate outcomes after each reassessment and update the care plan when goals are partially met or unmet.
• Connect families with support groups, financial-assistance pathways, and mental-health resources when psychosocial strain affects care adherence.

Exacerbation Progression Risk

Delayed response to increased sputum burden or breathing effort can accelerate lung damage.

Evaluation

Evaluate symptom trend, physical findings, and physiologic parameters over time. Core outcome priorities are airway-clearance effectiveness, reduced exacerbation burden, and long-horizon survival improvement.

Use patient report, direct cough observation, lung-auscultation findings, and vital-sign trends to judge control status. Reassess hydration, nutrition, and elimination status because systemic decline can worsen pulmonary outcomes.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
bronchodilators	Inhaled bronchodilator regimens	Improve airflow before airway-clearance interventions.
Mucus-thinning therapies	Ordered mucolytic regimens	Support secretion mobilization and airway clearance.
Anti Inflammatory Medications	Ibuprofen or corticosteroid pathways	Reduce airway inflammation burden in selected care plans.
antibiotics	Intermittent or continuous regimens	Target respiratory pathogens and reduce exacerbation frequency.
Pancreatic enzyme replacement	Pancrelipase-based plans	Improve digestion and nutrient absorption in pancreatic insufficiency.
Salt supplementation	Oral salt tablet pathways when ordered	Supports electrolyte balance in high-loss patterns.
CFTR modulators	Mutation-specific combinations	Use only for eligible genotypes; monitor response and tolerance.

Clinical Judgment Application

Clinical Scenario

A school-aged client with CF has increased cough, thicker sputum, fatigue, and reduced appetite over several days.

• Recognize Cues: Pulmonary and nutrition decline pattern with possible exacerbation.
• Analyze Cues: Airway obstruction and infection risk are increasing.
• Prioritize Hypotheses: Highest priorities are oxygenation protection and early infection management.
• Generate Solutions: Intensify airway-clearance schedule, optimize nutrition support, and coordinate provider reevaluation.
• Take Action: Intensify assessment, implement ordered respiratory therapies, and escalate for provider reevaluation.
• Evaluate Outcomes: Breathing effort decreases, sputum clearance improves, and intake begins to recover.

Related Concepts

• respiratory-system - Airway and gas-exchange framework for chronic obstruction risk.
• genetic-influences-on-cardiopulmonary-disorders - Inherited cardiopulmonary disease context.
• pneumonia - Frequent infectious exacerbation linkage in chronic secretion retention.
• oxygen-therapy - Escalation support during pulmonary decline.
• bronchiectasis - Long-term airway-damage overlap in recurrent infection-inflammation cycles.
• pulmonary-function-testing-and-pefr-zones - Functional decline quantification in serial follow-up.
• arterial-blood-gas-abg - Gas-exchange and acid-base trend support in severe exacerbation.
• stool-tests-for-bowel-function-evaluation - Malabsorption and fecal-fat evaluation context.

Self-Check

1. Why does CFTR dysfunction cause both pulmonary and gastrointestinal effects?
2. Which findings most strongly suggest a pulmonary exacerbation?
3. Why must nutrition surveillance be integrated with respiratory care in CF?